The physiological role of any of the epidermal growth factor (EGF) receptor tyrosine kinases has yet to be determined in zebrafish. We isolated a zebrafish homologue of EGFR (egfr) that shows a 63% amino acid overall identity to human EGFR but with 90% amino acid identity in the kinase domain. Whole mount in situ hybridization showed ubiquitous distribution of egfr transcripts during gastrulation, somitogenesis and later stages. When expressed in Chinese hamster ovary cells, zebrafish Egfr was a functional receptor that responded to EGF by receptor tyrosine phosphorylation and activation of MAP kinase. The function of zebrafish Egfr in vivo was determined by inhibiting its activity using EGFR kinase inhibitors and antisense morpholinos (MO), which inhibited Egfr kinase activity and translation of egfr messenger RNA into protein, respectively. The zebrafish is a particularly excellent model for studying cardiovascular development because zebrafish are transparent allowing direct visualization of the heart and circulation in the blood vessels. Inhibition of zebrafish Egfr activity in vivo impeded blood flow via the outflow tract into the aorta and impeded circulation in the axial and intersegmental vessels by 80 h postfertilization. Analysis of the heart showed that the heart chambers and pericardial sacs were dilated and the outflow tracts were narrowed. Together these results suggested that zebrafish Egfr has a cardiovascular function in the developing zebrafish that is required for normal circulation. q
Introduction
The epidermal growth factor (EGF) family consists of ten members in vertebrates, one in C. elegans and five in Drosophila (Olayioye et al., 2000; Yarden and Sliwkowski, 2001 ). EGF signaling is transduced by a family of four receptors. These include EGF receptor (EGFR), also known as ErbB1 or HER1 (human EGF receptor), ErbB2/ neu/HER2, ErbB3/HER3 and ErbB4/HER4 (Olayioye et al., 2000; Yarden and Sliwkowski, 2001 ). In addition, C. elegans expresses Let23 and Drosophila melanogaster expresses Drosophila epidermal growth factor receptor, both of which are EGF receptor homologues (Moghal and Sternberg, 1999; Yarden and Sliwkowski, 2001 ). EGFs and their receptors are regulators of cell proliferation, differentiation, survival, motility, and apoptosis (Olayioye et al., 2000; Yarden and Sliwkowski, 2001) . They regulate normal physiological processes such as embryonic development, wound healing, tooth growth, eyelid opening in newborn, development of hair follicles, and mammary gland morphogenesis. EGF receptors also contribute to pathology, for example, amplification and inappropriate activation of EGF receptor family members are associated with tumor growth (Blume-Jensen and Hunter, 2001; Yarden and Sliwkowski, 2001) , psoriasis (Jost et al., 2000) and cardiomyopathy (Asakura et al., 2002; Crone et al., 2002) .
Knockout methodology in mice has been used to determine EGF family and EGF receptor family functions in vivo. Embryos deficient in the EGFR ligands, either Egf, Transforming growth factor-a (Tgf-a) or Amphiregulin (Ar), are viable and fertile (Luetteke et al., 1999; Luetteke et al., 1993; Mann et al., 1993) . In contrast to ligand knockouts, mice deficient in Egfr exhibit severe defects (Chen et al., 2000; Miettinen et al., 1995; Sibilia et al., 1998; Sibilia and Wagner, 1995; Threadgill et al., 1995) . However, these phenotypes are strain-dependent. In some mouse strains, Egfr deficiency is embryonic lethal, in other strains the mice survive for at least 3 weeks. Abnormalities include placental defects, degeneration of the inner cell mass, progressive neurodegeneration and defects in epidermis, lung, kidney, brain, liver, semilunar heart valves and the gastrointestinal tract, suggesting that EGFR is involved in a wide range of cellular activities. In the case of the semilunar valves the severity of the Egfr knockout was greatly enhanced when Ptpn11 encoding protein-tyrosinephosphatase SHP2 was knocked out in addition to Egfr (Chen et al., 2000) .
We have previously analyzed the structure and function of several EGF family ligands and their receptors using cell cultures (Higashiyama et al., 1991; Elenius et al., 1997; Nishi et al., 2001) . To analyze EGF receptor function in vivo, we decided to use the developing zebrafish embryo. The zebrafish is an excellent model for demonstrating growth factor receptor function because of its rapid development, transparency and the ease of administering drugs (Chan et al., 2002; Lee et al., 2002) . Several methods are available to inactivate growth factor receptors in zebrafish. One way is to inhibit receptor tyrosine kinase receptors by administering kinase inhibitors to the zebrafish water. For example, vascular endothelial growth factor (VEGF) receptor-2 kinase inhibitors administered at the 1 -4 cell stage block developmental angiogenesis (Chan et al., 2002) . An alternative method is to inhibit receptor synthesis by injecting antisense morpholino oligos (MO) at the 1 -4 cell stage, a process known as 'knockdown' . While not a true genetic knockout, knockdowns achieve a similar goal of producing zebrafish deficient in a specific protein. Several MO knockdowns that affect cardiovascular function have been reported in zebrafish, for example, vegf , neuropilin-1 , gridlock (Zhong et al., 2001 ) and tbx5 (Garrity et al., 2002) .
Because of strain differences, the function of EGFR in mice has been ambiguous. Zebrafish afford the possibility of further analysis of EGFR function in a novel system. There have been no reports yet on the cloning, characterization and function of any zebrafish EGFs or EGF receptors. We report here the first cloning and functional analysis of the zebrafish orthologue of EGFR. Normal Egfr function was inhibited by treatment of zebrafish with EGFR kinase inhibitors and EGFR MO. These inhibitors yielded similar defects in the developing cardiovascular system including impeded outflow into the aorta, impeded circulation in the axial and intersegmental vessels (ISV), and dilated pericardial sacs and heart chambers. These results suggest that Egfr has a cardiovascular function in zebrafish required for normal blood circulation.
Results

Cloning and characterization of zebrafish Egfr
PCR and 5
0 RACE were used to isolate a full length zebrafish cDNA that was homologous to human, rat, mouse, and chicken EGFR. The zebrafish Egfr has 1191 amino acids, a molecular mass of 165 kDa and is 63% homologous to human EGFR. The protein tyrosine kinase domain of zebrafish Egfr is particularly well conserved, with about 90% homology, whereas the autophosphorylation domain is poorly conserved (Fig. 1A) . The tyrosine residues in human EGFR become phosphorylated in response to EGF and serve as docking sites for adapter proteins such as Shc, Grb2, Gab1, Src, SHP1, SHP2, Cbl, and PLC g (Olayioye et al., 2000) . These docking sites are all conserved in zebrafish Egfr (Fig. 1B) .
Egfr expression in zebrafish
Zebrafish Egfr was detected in 24 h post fertilization (hpf) embryos by western blotting as a 165 kDa protein (data not shown). Whole mount in situ hybridization was used to examine the expression pattern of zebrafish egfr during development (Fig. 2) . A ubiquitous distribution of egfr transcripts was found during gastrulation ( Fig. 2A,B) . From the 18-somite stage to 24 hpf, egfr is expressed in the floor plate of the neural tube, in the forebrain, hindbrain and in the gut endoderm ( Fig. 2C and D) . By 48 hpf, a low level of egfr transcripts was found throughout the embryo with prominent expression in the retina, brain and pectoral buds (Fig. 2E ). Similar expression patterns were seen at 56 and 72 hpf.
EGF activates zebrafish Egfr
To determine whether zebrafish Egfr was functional, the full length gene was transiently transfected into Chinese hamster ovary (CHO) cells which do not express endogenous EGFR, and the cells were incubated with recombinant human EGF. Western blotting with an anti-phospho EGFR antibody detected tyrosine phosphorylated zebrafish Egfr only after incubation with EGF (Fig. 3B ). In addition, western blotting with anti phospho Erk1/2 antibody demonstrated that EGF could induce phosphorylation of Erk1/2 (Fig. 3C ). Equal amounts of zebrafish Egfr were loaded on to the gel (Fig. 3A) . These results demonstrate that zebrafish Egfr can respond to human EGF. Cells expressing zebrafish Egfr were activated by other EGF family members besides EGF, including heparin-binding EGF-like growth factor (HB-EGF), betacellulin (BTC), TGF-a, and AR (data not shown). On the other hand, Neureglin 1 (NRG1) did not activate zebrafish Egfr consistent with NRG1 being a specific ligand for ErbB3 and ErbB4 (data not shown).
Inhibition of zebrafish Egfr activity in vitro by kinase inhibitors
The EGFR kinase inhibitor, PKI166, was tested for its ability to inhibit EGF-mediated human EGFR autophosphorylation in cultured HeLa cells which express abundant EGFR (Fig. 3D ) and in CHO cells transfected with zebrafish egfr (Fig. 3E) . Western blotting showed that for both cell types, EGF-mediated tyrosine autophosphorylation (Fig. 3D , lane 2 and Fig. 3E , lane 7) was inhibited in a dose-response manner, by PKI166 (Fig. 3D , lanes 3 -5 and Fig. 3E , lanes 8 -10), respectively. The IC 50 was in both cases about 1 nM. The same results were obtained with another EGFR kinase inibitor, AG1478 (data not shown) whereas VEGF receptor kinase inhibitors had no effect on zebrafish Egfr tyrosine autophosphorylation (not shown).
EGFR kinase inhibitors induce cardiovascular defects
Two EGFR kinase inhibitors, PKI166 (Fig. 4 B) and AG1478 ( Fig. 4C) were added to the embryo media at the 1 cell stage and at 24 h intervals thereafter. At 80 hpf kinase inhibitor-treated zebrafish had enlarged pericardial sacs that were dilated by fluid ð100%; n ¼ 42Þ ( Fig. 4B and C, Table 1) compared to control untreated zebrafish (Fig. 4A ) as determined by light microscopy. FITC dextran was microinjected into embryos at 56 and 80 hpf in order to visualize circulation in the heart and blood vessels by microangiography. Normal circulation via blood vessels, including the dorsal aorta (DA), caudal vein (CV), ISV, and dorsal lateral anastamozing vessels (DLAV) are shown in Fig. 4D and G. At 56 hpf circulation appeared fairly normal in the EGFR kinase inhibitor treated embryos (Fig. 4E) . However, by 80 hpf, circulation via the DA and ISV and DLAV was greatly diminished (Fig. 4H) . Some circulation was observed in the common cardinal vein (CCV). For comparison, VEGF kinase inhibitors which totally inhibit both axial and ISV development (Chan et al., 2002; Lee et al., 2002) were tested. At 56 hpf and 80 hpf no circulation was detected in either the axial vessels or in the ISV/ DLAV (Fig. 4F and Fig. 4I ), consistent with the previous studies with VEGFR kinase inhibitor (Chan et al., 2002; Lee et al., 2002) . Thus, the VEGFR kinase inhibitor yields a more severe vascular phenotype than the EGFR kinase inhibitor.
These EGFR kinase inhibitor phenotypes suggested that there might be a block that impedes blood flow. Microangiography of the heart at 80 hpf demonstrated enlarged hearts and little if any flow from the heart to the aorta (Fig. 5B ) compared to controls without EGFR kinase inhibitor (Fig. 5A ). Consistent with this impediment of blood flow out into the aorta, the outflow tract appeared to be narrowed or closed as shown by histological analysis of transverse serial sections (Fig. 5D ) compared to control (Fig. 5C) . A movie (Ullrich et al., 1984) (top) and the zebrafish Egfr cytoplasmic sequence (bottom) were aligned using a MultAlin program (Corpet, 1988) . Zebrafish Egfr amino acids identical to human EGFR are shown as dots. The cytoplasmic tyrosine kinase domains (TK) are shown within the bars and the rest of the sequence represents the autophosphorylation (AP) domain as predicted by Scansite (Yaffe et al., 2001) and Netphos/phosphobase analysis. Tyrosine residues conserved in human and zebrafish sequences are designated by closed triangles. Tyrosine residues that become phosphorylated and act as docking sites for adapter proteins are numbered. In human EGFR, Src homology 2 domain containing (Shc) binds to Y1148 and Y1173, phospholipase C g (PLC g) binds to Y1173 and Y992, growth factor receptor-bound protein 2 (Grb2) binds Y1068 and Y1086, Cbl binds Y1045 and src homology 2-containing tyrosine phosphatase 1 (Shp1) binds to Y1173 (Olayioye et al., 2000) .
indicated that kinase-inhibitor treated zebrafish also displayed regurgitation across the atrioventricular valve (not shown). There was regurgitant blood flow from the ventricle into the atrium and then from the atrium to the yolk sac. Schematics of the outflow tract narrowing and regurgitation in kinase inhibitor-treated embryos compared to control embryos are shown in Fig. 5E and F, respectively.
A temporal analysis of the effects of EGFR kinase inhibitor administration is shown in Table 2 . In one series kinase inhibitor was administered at the one cell stage and removed at either 24, 48 or 56 hpf, and embryos were analyzed at 80 hpf. Severe cardiovascular defects were detected in the 0 -80 hpf interval but not in the 0-56 hpf interval or shorter intervals before that. In a second series, EGFR kinase inhibitor was first added at 24, 36 or 48 hpf and embryos were analyzed at 80 hpf. Cardiovascular defects were detected in the 24-80 hpf, 36 -80 hpf but not in the 48-80 hpf intervals. Together these results suggest that the 36 -80 hpf interval is a critical one for inducing cardiovascular defects in response to inhibiting zebrafish Egfr activity in vivo.
EGFR morpholinos induce similar cardiovascular defects
Since it is possible that EGFR kinase inhibitors might not be totally specific, another approach to inhibiting Egfr function was used. MO inhibit the translation of mRNA into protein. To determine MO efficacy, zebrafish egfr mRNA was translated in an in vitro transcription and translation system, and analyzed by SDS-PAGE and autoradiography (Fig. 6A) . EGFR MO inhibited the translation of zebrafish egfr in a dose-dependent manner, with 85% inhibition at 10 mM whereas the 4 base mismatch control inhibited translation by only 5 -10% at the same concentration. A second MO (MO2) at 10 mM inhibited in vitro translation by 60-70% (not shown).
To test MO efficacy for inhibiting zebrafish Egfr protein translation in vivo, zebrafish embryos were injected with 0.2 mM MO at the 1 -4 cell stage and inhibition of translation into Egfr protein was measured at 24 hpf by western blotting. zebrafish egfr translation was inhibited in vivo by 85% with the EGFR MO, whereas there was a only a 15% inhibition by the 4 base mismatch control MO (Fig. 6B) . EGFR MO administered at the 1-4 cell stage and analyzed at 80 hpf, induced dilated pericardial sacs and heart chambers ( Fig. 7B ) compared to control (Fig. 7A) as had been observed above with administration of EGFR kinase inhibitor. The enlarged pericardiac sac and heart phenotype could be rescued by co-injection with zebrafish egfr mRNA (Fig. 7C) . Microangiography demonstrated that circulation was normal at 56 hpf (Fig. 7D) but that there was diminished circulation through the DA, CV, ISV and DLAV at 80 hpf (Fig. 7E) . These results indicate that both EGFR KI and MO induce similar cardiovascular defects.
The effects of EGFR KI and MO on zebrafish embryo cardiovascular development can be quantitated (Table 1 ). All of the 42 embryos treated with EGFR KI had enlarged hearts and flow defects compared to 47 -57% of the 177 embryos treated with EGFR MO. In rescue experiments Schematic of heart chambers of control (E) and kinase inhibitor-treated (F) zebrafish. The schematic depicts heart phenotypes observable in a time lapse movie made at 0.1 s intervals. The arrows depict blood flow. In controls, the blood flows normally from the atrium to the ventricle, through the outflow tract and into the aorta. In contrast, in zebrafish treated with EGFR kinase inhibitor, blood flows from the atrium to the ventricle during ventricular relaxation and regurgitates back into the atrium when the ventricle contracts. The outflow tract (OT) is depicted as being obstructed, thereby forcing blood back into the atrium.
when embryos were co-injected with MO and zebrafish egfr mRNA, enlarged hearts and circulation defects were observed in 26% and 18% ðn ¼ 39Þ of the embryos compared to 57% and 47% ðn ¼ 177Þ for MO alone, indicating that approximately 50 -60% of the embryos were rescued from the cardiovascular phenotype.
Discussion
Characterization of zebrafish Egfr
We have cloned and characterized for the first time a zebrafish orthologue of EGFR. Homology, structural, biological, and phylogenetic analysis indicates that of the various members of the EGF receptor family, zebrafish Egfr is most similar to the classical EGFR (Carpenter and Cohen, 1990) . Whereas, the overall homology to other vertebrate EGFR is 63%, the homology in the vertebrate EGFR tyrosine kinase domain is over 90% with total conservation of tyrosine phosphorylation sites. When expressed in CHO cells, zebrafish Egfr was functional and became tyrosine phosphorylated in response to the EGF family members known to activate mammalian EGFR, namely EGF, TGFa, AR, HB-EGF, and BTC, but not in response to NRG, which is a ligand for ErbB3 and ErbB4 (Olayioye et al., 2000) . Together these results demonstrate that zebrafish Egfr is a functional receptor that mediates signaling pathways as in mammalian systems.
Inhibition of zebrafish Egfr activity results in cardiovascular defects
To determine function in vivo, zebrafish Egfr activity was inhibited in two ways reflecting two different mechanisms of inhibition. One was to use EGFR kinase inhibitors which have been previously shown in mammalian systems to inhibit EGFR tyrosine phosphorylation, EGFdependent growth in cultured cells and tumor growth in a variety of xenograft models (Baker et al., 2002) . Two different EGFR kinase inhibitors were used, both of which totally inhibited EGF-mediated tyrosine phosphorylation of zebrafish Egfr in transfected CHO cells. However, since non-specific effects could occur, a second approach was to use MO which act by a totally different mechanism, inhibition of protein translation. Injection of MO has been shown to be a powerful, relatively simple and rapid method for generating loss-of-function for zebrafish growth factors and receptors, for example, vegf , and neuropilin-1 . MO have also been used to inhibit the translation of the gridlock (Zhong et al., 2001) and tbx5 (Garrity et al., 2002 ) genes resulting in cardiovascular defects. In this study two EGFR MOs were tested, the most potent of which inhibited in vitro translation by 85%.
The transparency of zebrafish makes it is relatively easy to see the functioning heart including the atrium and ventricle. Blood vessels leading out of and into the heart and the ISV are readily observable by microangiography. Zebrafish embryos can survive without a functioning circulation for up to seven dpf by cutaneous uptake of oxygen from the water (Rombough, 2002) and be analyzed for phenotype in this interim. The EGFR kinase inhibitors and MO were both found to affect cardiovascular development adversely in the zebrafish in a similar manner. Normally, blood circulates from the heart through the outflow tract into the aorta, through the DA and back to the heart through the caudal veins. There is also blood flow via the ISV which sprout from the DA and form the DLAV. In the presence of the inhibitors, however, microangiography at 80 hpf showed impeded blood flow out of the outflow tract into the aorta, and impeded circulation via the DA and via the ISV. The outflow tracts appeared to be narrowed as shown by both microangiography and histology. Time lapse photography detected regurgitation from the ventricle back into the atrium and from the atrium to the CCV (not shown). In addition, the hearts and pericardial sacs appeared to be enlarged. Myocyte hypertrophy or hyperplasia were not significant contributors to the cardiac enlargement since there was no obvious difference in the thickness of the heart wall, which is a 2-cell layer, between control and the treated embryos. Heartbeat was not affected either. Rather, enlargement of the heart appeared to be due primarily to dilated heart chambers. Together, these observations suggest a mechanism in which a narrowed outflow tract or defective valves imposes a greater hemodynamic afterload on the ventricle. As a consequence, the interventricular pressure increases resulting in chamber dilation and atrioventricular regurgitation (Hunter and Chien, 1999; Towbin and Belmont, 2000) . Narrowing of the outflow tract would block circulation out to the aorta and through the axial vessels and the ISV. There is the possibility that the impeded blood flow reflects defects in the integrity of axial vessels and ISV. However, these blood vessels appeared to be functional and undamaged since circulation appeared normal at 56 hpf, after these blood vessels were formed. We have previously found EGFR protein in the mouse heart (Iwamoto et al., 2003) . In situ hybridization of zebrafish heart cross-sections showed weak egfr expression at 72 hpf in the myocardium and in the region of the outflow tract. It may be, however, that sufficient zebrafish Egfr protein is available for receptor activation. Alternatively, it is possible that loss of Egfr activity in other cells, such as cardiac neural crest cells that migrate into the zebrafish heart and contribute to the myocardial cell lineage (Li et al., 2003) , indirectly results in abnormal heart function.
Temporal analysis indicated that kinase inhibitor needed to be administered before 36 hpf to be effective for inducing cardiovascular defects consistent with the observation that heart beat and blood circulation begins around 24 -28 hpf (Stainier, 2001; Isogai et al., 2001 ). The kinase inhibitors showed a stronger effect (defects in 100% of the zebrafish, n ¼ 42) than the MO oligos (defects in 47-57% of the zebrafish, n ¼ 177). The reason may be that MOs are injected into 1-4 cell stage embryos only and the injections are not always efficient. On the other hand, the EGFR kinase inhibitors are added directly to the zebrafish medium, no injection is needed, and EGFR kinase inhibitor can be added repeatedly through development.
Mammalian EGFR
There is just one previous report showing that EGFR is involved in heart development (Chen et al., 2000) . In this study EGFR was implicated as being required for normal semilunar, although not atrioventricular, valve development in mice. Mice homozygous for the hypomorphic Egfr allele waved-2 (EGFR wa2/wa2 ) exhibited semilunar valve enlargement resulting from overabundant mesenchymal cells. Egfr -/ -null mice with a CD1 background had similar defects and were embryonic lethal. However, the severity of the EGFR wa2/wa2 phenotype was greatly enhanced when Ptpn11, encoding the protein-tyrosine-phosphatase SHP2 was mutated as well as Egfr. These mice were embryonic lethal. Possible effects of EGFR knockout on circulation outside the heart were not reported but unlike zebrafish which can obtain oxygen through the skin and survive, analysis of circulation in an embryonic lethal mouse embryo would be difficult.
EGFR ligands
Loss of EGFR activity suggests a loss in the activity of one or more of the EGFR ligands. A good candidate would be HB-EGF. HB-EGF is a potent mitogen for aortic smooth muscle cells (Higashiyama et al., 1991) . It is expressed in cardiomyocytes, as is EGFR, and is a stimulator for hypertrophic cardiomyopathy (Asakura et al., 2002) . Hb-egf null mice have cardiac defects, such as enlarged cardiac valves and dilated ventricular chambers (Iwamoto et al., 2003) whereas Egf, Tgf-a, and Ar knockouts have normal heart valves (Chen et al., 2000) . We speculate that the effects of inhibiting Egfr activity in zebrafish may be in part due to loss of Hb-egf function which is mediated via Egfr. It is also possible that lack of Egfr, which heterodimerizes with Erbb2, Erbb3 and Erbb4, might affect the activities of these receptors.
EGF and EGF receptor families
In summary, we have isolated a zebrafish EGF receptor for the first time and shown it to be required for normal zebrafish cardiovascular development. The EGF and EGF receptor families contain at least seven and four members, respectively, none of which until now have been described in zebrafish. Our approach of testing the effects of kinase inhibitors and MO might be useful for analyzing the function of these growth factors and their receptors in the cardiovascular system. For example, ErbB2, ErbB3 and ErbB4 are receptor tyrosine kinases required for normal heart development in the mouse (Britsch et al., 1998; Erickson et al., 1997; Gassmann et al., 1995; Lee et al., 1995) . NRG, the ligand for ErbB3 and ErbB4, is also required for normal heart development (Gassmann et al., 1995; Meyer and Birchmeier, 1995) . So far, besides zebrafish egfr, we have cloned zebrafish hb-egf and two isoforms of zebrafish erbb3. When all the zebrafish EGF ligand/receptor genes are available, it should be possible to study the interactions of EGF family members and their receptors in a systematic manner in one organism.
Materials and methods
Materials
Rabbit and goat anti EGFR antibody were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti phospho-EGFR antibody was purchased from Upstate Biotechnology (Lake placid, NY). Anti phospho Erk 1/2 antibody which recognizes both Erk 1 p44 and Erk 2 p42 MAPK was purchased from Calbiochem (San Diego, CA). Recombinant human EGF was purchased from R&D (Minneapolis, MN). The EGFR tyrosine kinase inhibitor, PKI166 and the VEGFR-2 tyrosine kinase inhibitor, PTK787/ZK222585, were kindly provided by Dr Jaenette Wood (Novartis Pharma AG Basel, Switzerland). PTK787/ZK222585 was co-developed by Schering and Novartis. The EGFR tyrosine kinase inhibitor AG1478, was purchased from Calbiochem.
Zebrafish maintenance
Zebrafish were maintained in the Children's Hospital (Boston, MA) breeding colony at 28.5 8C on a 14 h light/10 h dark cycle. Embryos were collected from the natural mating of breeding pairs, raised at 28.5 8C, and staged as described (Kimmel et al., 1995) . Embryos older than 24 h postfertilization (hpf) were raised in 0.2 mM 1-phenyl-2-thiourea (Sigma, St Luis, MO) to prevent pigment formation.
Isolation of zebrafish egfr
Degenerate PCR: Degenerate primers based on conserved EGFR tyrosine kinase sequences from human, mouse, rat, and chicken were synthesized. The PCR reaction used a forward primer corresponding to the amino acid sequence VQIAKGM found at position 819-826 of human EGFR, in combination with the reverse primer corresponding to the sequence MARDP(P/Q)R(Y/F), found at position 971-978 of human EGFR. The primer for VQIAKGM was 5
0 . An inosine residue was used at nucleotide positions where complete degeneracy was required. An adult zebrafish kidney cDNA library was used as a template. Colony hybridization: cDNAs were cloned from adult zebrafish kidney random and oligo-dT cDNA libraries by hybridization with degenerate PCR products of zebrafish egfr. 5 0 RACE: To obtain full length clones, the 5 0 sequence of zebrafish egfr was obtained by RT-PCR from 24 hpf embryo total RNA, using the SMART-RACE cDNA Amplification Kit (BD Bioscience Clontech, Palo Alto, CA) according to manufacturer's suggested protocol. The primers used for 5 0 RACE were antisense zebrafish egfr: 5 0 -ACTCCGGCGATTTCACTGGCAG-GAAT-3 0 , and anti-sense nested zebrafish egfr: 5 0 -CGTACGCCTCATCCATTATCTCCTTG-3 0 . The 5 0 RACE products were cloned into pGEM-T-easy (Promega, Madison, WI) and confirmed to include the start codon and 5 0 UTR sequences of zebrafish egfr. To generate full length zebrafish egfr (zEGFR/pBK-CMV) the 5 0 RACE product in pGEMTeasy was excised by Eco RI and Bsi WI and subcloned into Eco RI and Bsi WI site of an adult zebrafish kidney cDNA library clone which encoded the 3 0 end of zebrafish egfr.
Egfr overexpression
CHO cells were purchased from American Type Culture Collection (ATCC, Manassas, VA) and maintained in Ham's F-12 medium supplemented with 10% fetal calf serum, 100 mg/ml streptomycin, 100 units/ml penicillin, and 2 mM L-glutamine, in 5% CO 2 . Cells were plated at a density of 30,000 cell/well in 6 well culture plates, grown for 24 h, and transiently transfected with 1 mg of control vector, pcDNA3.1/V5-His/lacZ (Invitrogen, Carlsbad, CA) or zEGFR/pBK-CMV using the FuGene 6 transfection reagent (Roche Applied Science, Indianapolis, IN) following the manufacturer's instructions. Cells were grown for an additional 36 h for western blot analysis.
In situ hybridization of temporal stages
Expression of zebrafish egfr was detected by whole mount in situ hybridization as described previously . Briefly, zebrafish egfr cDNA was used as a template to synthesize a digoxigenin-labeled antisense riboprobe. Embryos were fixed in 4% paraformaldehyde overnight and then permeabilized by proteinase K treatment prior to hybridization. After the occurrence of a color reaction with alkaline phosphatase substrates, the embryos were mounted in glycerol and photographed.
Western blotting of zebrafish Egfr
For western blot, transfected CHO cells or twenty embryos were lysed with SDS-PAGE sample buffer and boiled for 5 min. The total lysates were resolved by 6 and 12% SDS-PAGE for EGFR and Erk1/2, respectively. For detection of EGFR or phospho-Erk1/2, the membranes were incubated with rabbit anti-EGFR antibody (Santa Cruz Biotechnology, Inc; 1:2000 dilution) or rabbit anti-phosphoErk1/2 antibodies (Calbiochem; 1:2000 dilution). For detection of phospho-EGFR, membranes were incubated with anti-phospho EGFR monoclonal antibody 9H2 (Upstate). The bound antibodies were visualized using a horseradish peroxidase-conjugated anti-rabbit IgG (Santa Cruz; 1:5000) or anti-mouse IgG (Amersham Pharmacia Biotech, Piscataway, NJ; 1: 10,000) and an ECL kit (Perkin Elmer Life Science, Boston, MA).
In vitro transcription and translation assay
In vitro transcription and translation of zebrafish egfr was performed using the TNT Quick Coupled Reticulocyte Lysate System (Promega) as described previously with the following modifications: the 25 ml reaction contained 0.5 mg of zEGFR/pBK-CMV plasmid and varying amounts of MO (0, 100 nM, 1 mM, and 10 mM). The reaction was incubated at 28 8C for 90 min and stopped by chilling to 4 8C. Five ml from the reaction mix were analyzed by 6% SDS-PAGE and visualized by autoradiography. Relative protein levels were quantitated by densitometric analysis using the NIH Image software.
Kinase inhibitors
The tyrosine kinase inhibitors PKI166, AG1478 and PTK787/ZK22285 were dissolved in DMSO at a 10 mM stock solution. The inhibitor stock solutions were diluted into embryo medium (Westerfield, 1995) and 3 ml of embryo medium were added to each well of a 6 well plate containing twenty zebrafish embryos at the one cell stage which were soaked in the medium and incubated at 28 8C. For temporal analysis of the effects of EGFR kinase inhibitors, kinase inhibitors were administered at the one cell stage and at 24 h intervals thereafter. At these intervals, the embryo media containing inhibitor were removed and the embryos were washed with fresh embryo media three times. In another series, kinase inhibitors were added for the first time at 24, 36 or 48 hpf All of embryos were analyzed at 80 hpf. The zebrafish egfr insert was subcloned into pXT7 which was obtained from Dr S. Sokol (Beth Israel, Boston). To generate capped mRNA, plasmids were linearized by SalI and transcribed with T7 RNA polymerase using the mMESSAGE mMACHINE T7 in vitro transcription kit (Ambion, Inc., Austin, TX) according to the manufacturer's instructions. For microinjection of MO into zebrafish, from 0.1 to 1 mM of MO in approximately 500 pl were dissolved in Danieau buffer and injected into 1 -4 cell stage embryos. For rescue experiments, 0.2 mM of MO and 1 mg/ml of mRNA were injected into 1 -4 cell stage embryos.
Imaging and histology
Living zebrafish embryos were visualized with an Olympus SZX12 stereomicroscope and photographed using an Olympus DP11 digital camera (Olympus, Tokyo, Japan). For histology, embryos were fixed overnight in 4% paraformaldehyde in PBS at 4 8C and embedded in paraffin in transverse orientation. Serial sections were cut and stained with hematoxylin -eosin. Images were captured digitally on a Nikon ECLIPSE E600 microscope (Nikon, Tokyo, Japan) fitted with OPTRONICS Digital Output system (OPTRONICS, Goleta, CA), and further processed using Adobe Photoshop software (Adobe, San Jose, CA). Microangiography using FITC-dextran was previously described .
